

Share Allotments and Cleansing Notice

Medical technology company Singular Health Group Limited (ASX: SHG) (Singular Health or the Company) advises that it has today issued 8,095,805 fully paid ordinary shares (Shares) pursuant to:

- The issue of 428,571 Shares to PNS upon receipt of \$150,000 investment pursuant to placement previously announced on 19 June 2025;
- the exercise of 381,818 unlisted options with an exercise price of \$0.10 and expiring 26 June 2026, raising \$38,181.80.;
- the exercise and conversion of 4,500,000 vested performance rights previously issued in January 2024 to Marin and Sons; and
- the issue of 2,785,416 Shares in respect of consulting services provided to the Company.

Please refer to the respective Appendix 2A's applying for the quotation of the above Shares for further details.

Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Corporations Act") that:

1. the Company on 10 September 2025 issued 8,095,805 Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. the Company is providing this notice under section 708A(5)(e) of the Corporations Act;
3. as at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. sections 674 and 674A of the Corporations Act; and
4. as at the date of this notice, there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company.

This announcement is authorised for release by the Board of Directors for the Company.

For further information contact:

Denning Chong
Managing Director & CEO
denning@singular.health
1300 167 795

Paul Berson
Investor Relations
paul@corporatestorytime.com
+61 421 647 445

For personal use only

About Singular Health

Singular Health is a Western Australian, ASX-listed (ASX: SHG) medical technology company on a mission to create a seamless and integrated healthcare ecosystem where the full value of medical imaging records is unlocked, enabling universal access and promoting interoperability to maximise patient outcomes.

Singular Health's 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD[®] is cleared for diagnostic use in the United States.

To learn more, visit <https://singular.health> and <https://investors.singular.health/>

For personal use only